From September 17 to 19, 2021, the Henan Provincial Medical Association's Gynecological Oncology Academic Annual Conference was successfully held in Henan Hotel in a combination of online and offline. Kan Chengquan, Party Secretary and Director of Henan Health Commission, Wang Wei, Vice President and Secretary General of Henan Medical Association, Academician of Chinese Academy of Engineering, Professor Martin of Tongji Hospital, Huazhong University of Science and Technology, Sun Yingpu, Vice President of the First Affiliated Hospital of Zhengzhou University, Huazhong Science and Technology Professor Wang Shixuan from Tongji Hospital of University, Director Wei Zhengqiang of Chinese Journal of Practical Gynecology and Obstetrics, honorary chairman of Henan Medical Association Gynecological Oncology Branch, Professor Qiao Yuhuan from the First Affiliated Hospital of Zhengzhou University, former chairman of Henan Medical Association Gynecological Oncology Branch, Henan Provincial Oncology Professor Wang Li, Director of the Hospital's Department of Gynecology, Chairman of the Gynecological Oncology Branch of Henan Medical Association, Director of the Obstetrics and Gynecology Department of the First Affiliated Hospital of Zhengzhou University, and Professor Guo Ruixia, Director of Gynecology, attended the opening ceremony. Gynecological Oncology of Henan Medical Association also participated in the opening ceremony Vice chairmen, standing committee members and youth committee chairmen and vice chairmen of the branch, group leader and deputy group leader of the Gynecological Oncology Radiotherapy Group, Colposcopy and Cervical Pathology Group.

The theme of this conference is "Standardization, Accuracy, Minimally Invasive, Communication, and Improvement". It is divided into 4 venues and lasted 2.5 days. 75 well-known experts from outside the province and 37 from within the province gave academic lectures. The conference has a variety of forms, including surgical video competition, young physicians' excellent paper evaluation, difficult case discussion, discussion and comment on gynecological malignant tumor MDT cases, colposcopy training before the conference, and a special event "Chinese Medicine in Gynecological Tumors" Application" seminar. The content of this conference was rich, the lectures were wonderful, and the participants were enthusiastic about learning. More than 115,600 people attended the conference online and offline. Mengyang Pharmaceutical was honored to be invited to participate in this meeting, and brought the company's leading product Shengbai Oral Liquid (Mixture) to display at the conference.

Mengyang Pharmaceutical took the company's flagship product Shengbai oral liquid (mixture) to display at the meeting

Live

At the opening ceremony, Chairman Guo Ruixia delivered a speech: The incidence of the three major gynecological malignancies, cervical cancer, endometrial cancer, and ovarian cancer, remains high and is still one of the major diseases that threaten women's health, fertility, family happiness, and even life. With the advancement of medical science, the clinical practice of gynecological oncology is undergoing profound changes. The development of surgical concepts and skills and the application of various new drugs are changing the treatment mode of gynecological tumors, but the task of prevention and control of gynecological tumors is still very arduous: we still have a long way to go to achieve the elimination of cervical cancer by 2030 proposed by the World Health Organization; prevention We have no good strategies for ovarian cancer and endometrial cancer; we need to overcome difficulties to improve the long-term survival of advanced ovarian cancer, cervical cancer, and endometrial cancer. We gynecologic oncologists are, and will continue to be, faced with serious challenges.

Academician Martin said in his speech that in March this year, the Fourth Session of the Thirteenth National People's Congress voted and passed a resolution on the "14th Five-Year Plan" and the 2035 long-term goal outline. The "Planning Outline" clearly stated that the "14th Five-Year Plan" During the period, it will "comprehensively promote the construction of a healthy China" and put "protecting people's health in a strategic position of priority development". Malignant tumors are one of the major diseases that endanger people's health. The strategic deployment of the party and the country is the responsibility and mission of every medical worker. This annual academic meeting of gynecological oncology is a concrete example for gynecological oncologists to implement the country's promotion of the construction of a healthy China. Actions will definitely bring more help to future clinical work, and patients with gynecological tumors will definitely receive more effective treatment in the future.

Director Kan Quanquan introduced the current prevention and treatment of gynecological tumors in our province. He pointed out that Henan is a province with a large population, a large base of gynecological tumors, and a high incidence of cervical cancer. Everyone should study the latest research progress and achievements in the field of gynecological oncology through this academic conference, and apply new knowledge and new technologies to practical work as soon as possible. , to better serve the health of the people of the province.

This conference has a strong lineup of experts, a gathering of big names, and a warm atmosphere on the scene. Focusing on the cutting-edge progress, hot issues and development trends in the field of gynecological tumors and minimally invasive gynecology, online and offline learning and communication will be carried out through various forms such as academic lectures, case sharing, paper exchanges, and surgical videos. Experts and professors provided answers, academic discussions and experience exchanges on hot topics in gynecological oncology, and shared their unique insights on cutting-edge issues in the field of gynecological oncology.

The success of this conference has further improved the level of diagnosis and treatment of gynecological tumors in my country, vigorously promoted the continued development of gynecological tumors, and benefited the majority of patients with gynecological tumors.

Shengbai oral liquid (mixture), the exclusive product of Mengyang Pharmaceutical Medical Insurance, has always played an important role in ensuring the smooth progress of radiotherapy and chemotherapy for patients with gynecological tumors. It can reduce the incidence of severe myelosuppression, reduce the risk of interruption of anti-tumor treatment, and improve clinical symptoms of patients It has been recognized by tens of thousands of doctors and patients in terms of improving the quality of life of patients, and has been included in the 2020 edition of the "National Pharmacopoeia", and has been rated as a "Chinese patent medicine brand with clinical value" by the China Association of Traditional Chinese Medicine, and has been included in the top ten of the 2019 edition. Three-five textbooks "Hematology of Traditional Chinese Medicine" and "Interpretation of Traditional Chinese Medicine Diagnosis and Treatment Plans and Pathways for Predominant Blood Diseases" are national clinical pathways (tumor, blood disease volume), diagnosis and treatment guidelines, and expert consensus recommended treatment drugs. As a responsible and responsible national pharmaceutical company, Mengyang Pharmaceutical has assisted the smooth progress of this conference throughout the process, and will actively participate in more academic conferences in the future, building an academic exchange platform for experts, promoting the development of the tumor industry, Do our best to benefit the majority of cancer patients.